CTRI/2022/09/045934招募中4 期
An observational, 24 week, open-label, multi-center,prospective post marketing surveillance study to evaluate thesafety, tolerability and patient treatment experience (PTE) ofmepolizumab administration via autoinjector for adult patientsaged 18 years or older suffering with severe eosinophilicasthma.
试验速览
- 阶段
- 4 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Patients suffering from severe refractory eosinophilic asthma who have an indication from prescribing physician to start or have already started an add on treatment of mepolizumab by SC administration by patients or caregivers at home or healthcare providers in-clinic using a ready to use prefilled autoinjector
排除标准
- •Patients with other conditions that could lead to elevated eosinophils such as Hyper eosinophilic Syndromes including Churg-Strauss Syndrome or
- •Eosinophilic Esophagitis Patients with a known pre existing parasitic infestation within 6 months prior to Visit 1 should be treated appropriately
- •before inclusion in the study
研究者
相似试验
进行中（未招募）
不适用
A 24-month, multicenter, randomized, open label non inferiority study of efficay and safety comparing concentration- controlled Certican in two doses (1.5 and 3.0 mg/day starting doses) with reduced Neoral versus 1.44 Myfortic with standard dose Neoral in de-novo renal transplant recipientsPrevention of the rejection in adult patients receiving a de-novo renal transplant in combination with Neoral and corticosteroidsMedDRA version: 14.1Level: PTClassification code 10023439Term: Kidney transplant rejectionSystem Organ Class: 10021428 - Immune system disordersEUCTR2005-002854-22-ITOVARTIS FARMA825
进行中（未招募）
不适用
A 24-month, multicenter, randomized, open-label non-inferiority study of efficacy and safety comparing two exposures of concentration-controlled Certican with reduced Neoral versus 3.0g MMF with standard dose Neoral in de novo heart transplant recipients. -de novo heart transplantationEUCTR2005-003413-32-GBovartis Pharma Services AG590
进行中（未招募）
1 期
A 24-month, multicenter, randomized, open-label non-inferiority study of efficacy and safety comparing concentration-controlled Certican® in two doses (1,5 and 3,0 mg/day starting doses) with reduced Neoral® versus 1,44 g Myfortic® with standard dose Neoral in de novo renal transplant recipientsrenal transplantationMedDRA version: M15Classification code 10038533EUCTR2005-002854-22-SKovartis Pharma Services AG
进行中（未招募）
不适用
A 24-month, multicenter, randomized, open-label non-inferiority study of efficacy and safety comparing concentration-controlled Certican® in two doses (1.5 and 3.0 mg/day starting doses) with reduced Neoral? versus 1.44 g Myfortic? with standard dose Neoral in de novo renal transplant recipientsEUCTR2005-002854-22-SEovartis Pharma Services AG825
进行中（未招募）
1 期
A 24-month, multicenter, randomized, open-label non-inferiority study of efficacy and safety comparing concentration-controlled Certican® in two doses (1.5 and 3.0 mg/day starting doses) with reduced Neoral® versus 1.44 g Myfortic ® with standard dose Neoral® in de novo renal transplant recipients -renal transplantationEUCTR2005-002854-22-GBovartis Pharma Services AG